ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-10-31 02:58Group 1 - The core point of the news is that Anke Bio's stock price increased by 5.09% to 10.74 CNY per share, with a trading volume of 334 million CNY and a turnover rate of 2.60%, resulting in a total market capitalization of 17.963 billion CNY [1] - Anke Bio, established on September 28, 2000, and listed on October 30, 2009, is primarily engaged in the research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1] - The company's main revenue sources are gene engineering drugs (88.24%), external patches (11.67%), and other supplementary products (0.09%) [1] Group 2 - Among Anke Bio's top ten circulating shareholders, a fund under Yinhua Fund has increased its holdings by 191,300 shares in the third quarter, now holding 11.2177 million shares, which accounts for 0.92% of the circulating shares [2] - The fund, named Innovation Medicine (159992), has a total scale of 12.005 billion CNY and has achieved a year-to-date return of 28.21%, ranking 2060 out of 4216 in its category [2] - The fund's performance over the past year shows a return of 23.93%, ranking 2220 out of 3889, while it has incurred a loss of 10.74% since its inception [2]